Figure 5.

AHR in γδ T cell-deficient recipients reconstituted with genetically CD8-deficient Vγ4⁺ cells from “CD8-restored donors”, after intra-peritoneal sensitization and airway challenge with OVA (2ip3N protocol). (a-d) Lung resistance (R_L) and dynamic compliance (C_dyn) as percent changes from saline controls in relation to increasing doses of aerosolized MCh. Recipients: B6.TCR-Vγ4/6^−/− mice; donors: B6.CD8α^−/− mice. Treatments: none (NT), systemic sensitization and airway challenge (2ip3N), 2ip3N plus Vγ4⁺ cells from 2ip3N-treated donors. Donors: The donors of the Vγ4⁺ cells either remained non-restored or were restored with splenocytes from 2ip-treated B6.TCR-β^−/−/δ^−/− mice, including the following fractions: (a) whole spleen, (b) magnetic bead-selected CD8α⁺ or CD8α⁻ splenocytes, or (c) DC-enriched, magnetic bead-selected CD8α⁺ or CD8α⁻ DCs. (d) Donors of Vγ4⁺ cells were restored with nylon wool non-adherent, magnetic bead-selected CD8α⁺ T cells from 2ip-treated B6.TCR-δ^−/− mice.

Recipients: (a) untreated or after 2ip3N plus Vγ4⁺ cells from non-restored donors or donors that were restored with whole spleen (* 2ip3N plus Vγ4 cells compared with 2ip3N plus Vγ4 cells from donor restored with whole spleen, # non-treated compared with 2ip3N plus Vγ4 cells from non-restored donor); (b) untreated or after 2ip3N plus Vγ4⁺ cells from 2ip3N-treated donors restored with CD8-enriched or –depleted splenocytes (* non-treated compared with 2ip3N plus Vγ4 cells from donors reconstituted with CD8⁻ splenocytes, # 2ip3N plus Vγ4 cells from donors reconstituted with CD8⁻ splenocytes compared with 2ip3N plus Vγ4 cells from donor reconstituted with CD8⁺ splenocytes); (c) untreated or after 2ip3N plus Vγ4⁺ cells from donors restored with CD8⁺ or CD8⁻ splenic DCs or with non-DCs (mostly CD8⁻) (* non-treated compared with 2ip3N plus Vγ4 cells from donor restored with non-DCs or # with CD8⁻ DCs, $ 2ip3N plus Vγ4 cells from donor restored with CD8⁺ DCs compared with 2ip3N plus Vγ4 cells from donor restored with non-DCs or # with CD8⁻ DCs; (d) untreated or after 2ip3N or 2ip3N plus Vγ4⁺ cells from donors restored with CD8α⁺ T cells (* non-treated compared with 2ip3N, # non-treated compared with 2ip3N plus Vγ4 cells from donors reconstituted with CD8α⁺ T cells, + there was no significant difference in R_L between 2ip3N and 2ip3N plus Vγ4 cells from donors reconstituted with CD8α⁺ T cells, with exception of the response to 12.5 mg MCh).